JUNE 22, 2026, EAST SYRACUSE, NY – ProAct, Inc., breaks down the biggest drug trend shifts so you don’t have to. Each year, the employee owners of ProAct come together to evaluate the pharmacy trends that shaped plan sponsor spend over the previous twelve months and to assess the forces that will continue to influence costs in the year ahead.
While the total market experienced a 12.5% increase and benefit spend benchmarks reached approximately 8%, ProAct’s overall trend of 7.4% demonstrates our continued ability to effectively manage cost growth and deliver meaningful savings compared to the broader industry.
In this year’s annual Drug Trend Report, we provide a clear, data driven view of the trends impacting prescription drug spend today, along with practical insight into what plan sponsors should be preparing for next. Our analysis blends industry wide data with ProAct specific experience, allowing us to not only identify emerging cost drivers, but also demonstrate how thoughtful clinical oversight, formulary strategy, and member engagement can meaningfully influence outcomes.
As an employee-owned pharmacy benefit manager, our approach is grounded in disciplined clinical and utilization management strategies, particularly in high-impact categories such as GLP-1 therapies. Through thoughtful formulary design, prior authorization controls, and ongoing monitoring, we have been successful in slowing the rate of growth in this category — helping plan sponsors navigate one of the fastest-growing areas of spend without sacrificing appropriate access to care.
Key Takeaways
• Three of the top five growing products are GLP-1s.
• Humira and Stelara sales are starting to see a decrease due to biosimilar alternatives.
• GLP-1 sales grew 33.5% over the last twelve months and account for 59% of the diabetes market.
• Oncology and obesity will drive spend growth through 2029.
Download a copy of the 2026 Drug Trend and Pipeline Report here: https://info.proactrx.com/dtr-2026
About ProAct, Inc.
ProAct, Inc., is a 100% employee-owned pharmacy benefit management (PBM) company. ProAct is a part of the KPH Healthcare Services family of companies, which includes Kinney Drugs. ProAct empowers clients to take charge of their pharmacy benefit plans by combining high-touch service with the latest in PBM technology. ProAct manages the dispensing of prescription drugs through its mail order pharmacy, ProAct Pharmacy Services, as well as through its national retail pharmacy network consisting of over 64,000 pharmacies in the United States, Puerto Rico, Guam, and the Virgin Islands. For more information, visit www.proactrx.com.
